Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ALXO 
Alx Oncology Holdings (ALXO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ALXO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -9.1% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.23M USD | Price to earnings Ratio - | 1Y Target Price 2.92 |
Price to earnings Ratio - | 1Y Target Price 2.92 | ||
Volume (30-day avg) 1053050 | Beta 1.01 | 52 Weeks Range 0.59 - 17.82 | Updated Date 04/1/2025 |
52 Weeks Range 0.59 - 17.82 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.58 |
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.3902 | Actual -0.4401 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -45.62% | Return on Equity (TTM) -88.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -84840245 | Price to Sales(TTM) 5906.24 |
Enterprise Value -84840245 | Price to Sales(TTM) 5906.24 | ||
Enterprise Value to Revenue 4254.36 | Enterprise Value to EBITDA -2.35 | Shares Outstanding 53384100 | Shares Floating 32339047 |
Shares Outstanding 53384100 | Shares Floating 32339047 | ||
Percent Insiders 2.11 | Percent Institutions 89.36 |
Analyst Ratings
Rating 3.86 | Target Price 7.67 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alx Oncology Holdings
Company Overview
History and Background
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company founded in 2015. They focus on developing therapies to block the CD47 checkpoint pathway, helping immune cells recognize and kill cancer cells.
Core Business Areas
- ALX148 (Evorpacept) Development: Lead product candidate evorpacept is a CD47 blocker in clinical trials for various cancers. It's designed to minimize anemia, a common side effect of other CD47 inhibitors.
- Research and Development: Engaged in preclinical research to develop new immuno-oncology therapies.
Leadership and Structure
Jaume Pons, Ph.D. is the President and CEO. The company has a board of directors overseeing strategic direction and governance.
Top Products and Market Share
Key Offerings
- Evorpacept (ALX148): Evorpacept is their lead product, a CD47 blocker currently in clinical trials. Revenue is currently $0, as it is not yet approved for commercial use. Competitors include Gilead (Magrolimab) and AbbVie (ABBV) (Lemzoparlimab).
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, driven by the potential of harnessing the immune system to fight cancer. The CD47/SIRPu03b1 pathway is a validated target, and companies are developing therapies to disrupt this interaction.
Positioning
ALX Oncology is positioned as a company developing a differentiated CD47 blocker (Evorpacept) with a potentially improved safety profile compared to competitors, reducing anemia.
Total Addressable Market (TAM)
The total addressable market for CD47-targeted therapies is estimated to be in the billions of dollars. ALX Oncology is attempting to capture a segment of this TAM through its unique approach to CD47 inhibition.
Upturn SWOT Analysis
Strengths
- Differentiated CD47 blocker (Evorpacept) with potentially improved safety profile.
- Strong scientific leadership team.
- Focus on a validated target (CD47/SIRPu03b1 pathway).
Weaknesses
- Clinical stage company with no approved products and therefore no revenue.
- Dependent on the success of Evorpacept.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Positive clinical trial results for Evorpacept.
- Partnerships with larger pharmaceutical companies.
- Expansion into new cancer indications.
Threats
- Competition from other CD47 blockers, including those from larger companies.
- Clinical trial failures.
- Regulatory hurdles.
- Difficulty raising capital.
Competitors and Market Share
Key Competitors
- GILD
- ABBV
- IMMU
Competitive Landscape
ALX Oncology competes with other companies developing CD47 inhibitors. Their differentiated approach focuses on minimizing anemia. Competition is intense, with both large and small companies in the space.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth is reflected in its pipeline progress and R&D spending.
Future Projections: Future growth projections are dependent on successful clinical trials and potential commercialization of Evorpacept.
Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials and presenting clinical data at medical conferences.
Summary
ALX Oncology is a clinical-stage company with a promising CD47 blocker, Evorpacept. The company's success hinges on positive clinical trial results and securing partnerships. They face strong competition and need to manage their cash runway carefully. The potential for a differentiated safety profile is a key strength.
Similar Companies
- IMMU
- GILD
- ABBV
- FATE
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (FactSet, Reuters)
Disclaimers:
The data provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alx Oncology Holdings
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-07-17 | CEO & Director Mr. Jason W. Lettmann | ||
Sector Healthcare | Industry Biotechnology | Full time employees 80 | Website https://www.alxoncology.com |
Full time employees 80 | Website https://www.alxoncology.com | ||
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.